The available evidence presents Polar Capital Global Healthcare Trust (PCGH) as a concentrated, actively managed healthcare vehicle whose recent repositioning has favored pharmaceuticals, healthcare services and biotech over medical equipment. It also places that profile within a wider capital-allocation environment dominated by large-cap technology, artificial intelligence and related growth themes. The evidence does not provide a direct PCGH holding, valuation, earnings or operating claim for Eli Lilly & Co. (LLY); its relevance to LLY is therefore thematic and contextual rather than a company-specific investment thesis.
PCGH’s portfolio changes suggest that specialist healthcare investors are becoming more selective. They are directing capital toward businesses with stronger product cycles, durable demand or more visible earnings, while reducing exposure to parts of the medical-technology market where growth has slowed and valuations have become stretched. This backdrop may support pharmaceutical leaders such as LLY, but it also demonstrates that healthcare capital remains subject to sector rotation, valuation discipline and competition from powerful technology narratives.
Portfolio Composition and Concentration
Broader capital-allocation context
The most robust evidence concerns the composition and concentration of the wider investment landscape. Fidelity Contrafund’s holdings are dated July 9, 2026 1. Domestic equities account for 89.4% of net assets 1, while developed and emerging markets represent 5.4% and 3.3%, respectively 1. Its ten largest holdings account for 46.3% of net assets, and the fund is explicitly described as highly concentrated in its largest positions 1. The portfolio has a pronounced large-cap technology and communication-services bias, with substantial exposure to artificial-intelligence, cloud and semiconductor infrastructure 1. Meta represents 7.662% of net assets 1, while Apple and Microsoft represent 3.173% and 2.165%, respectively 1.
This concentration indicates that technology-led growth remains a dominant destination for equity capital. For a large-cap pharmaceutical company such as LLY, the implication is not necessarily adverse, but it does create an opportunity cost: healthcare equities must compete for investor attention and valuation support against an exceptionally strong set of AI-related growth narratives.
Contrafund also has considerable exposure to private or non-listed growth companies, including SpaceX, OpenAI, Anthropic, Databricks, Canva, Stripe and other venture-style assets 1. SpaceX alone represents 6.203% of net assets 1, while private-company exposures such as Anthropic remain individually small 1. The portfolio-listing methodology includes both direct holdings and the fund’s pro rata share of underlying non-money-market Fidelity Central Funds 1. Apparent position sizes and portfolio breadth should therefore be interpreted with care. Even so, these holdings demonstrate that investors are willing to allocate significant risk capital to disruptive growth themes rather than exclusively to established pharmaceutical platforms.
PCGH’s healthcare allocation
PCGH offers a more focused view of healthcare-sector positioning. As of May 31, 2026, pharmaceuticals represented 42.3% of the portfolio 2. Life-sciences tools and services accounted for 8.2% 2, healthcare equipment for 7.7% 2, distributors for 2.3% 2, and facilities for 0% 2. The trust had increased the number of pharmaceutical companies among its ten largest holdings from five to six 2, while its top ten holdings represented 52.2% of the portfolio 2.
The leading positions included Roche at 6.3%, UnitedHealth at 6.1%, AstraZeneca at 5.5%, Thermo Fisher at 4.9%, Teva at 4.8%, CVS at 4.4%, Cigna at 3.7%, Novo Nordisk at 3.6% and Merck KGaA at 3.4% 2. LLY is not identified among these holdings. The allocation nevertheless confirms that pharmaceutical leaders, metabolic-health-adjacent businesses and healthcare-services companies remain central to specialist healthcare portfolios.
The concentration is meaningful. PCGH is not attempting to reproduce the healthcare market in miniature; it is expressing selected views through a relatively small number of positions. As in the older division of labor, specialization can increase productivity, but it also makes the result more dependent on the judgment of the specialist. Here, security selection is as important as broad sector exposure.
Active Repositioning Within Healthcare
The portfolio changes point to active intra-sector repositioning rather than a uniform allocation to healthcare. Between November 2025 and May 2026, PCGH reduced healthcare equipment from 24.2% to 7.7%, citing slowing top-line growth, a lack of new product cycles and stretched valuations 2. Abbott Laboratories, UCB, Genmab, Sandoz, Exact Sciences and Edwards Lifesciences were replaced in the top ten by Roche, UnitedHealth, CVS, Cigna, Novo Nordisk and Merck KGaA 2.
This movement toward pharmaceuticals and healthcare services suggests that managers are favoring stronger product cycles, more durable demand or greater earnings visibility over segments of medical technology whose growth and valuations have moderated. The direction is potentially supportive for LLY if its innovation pipeline and commercial execution remain strong. It does not, however, establish anything about LLY’s own pipeline, valuation, market share or portfolio weight. No claim identifies LLY as a PCGH or Contrafund holding, and the numerous small private-company and specialist healthcare positions cannot be used to infer direct exposure to LLY.
PCGH’s international composition further broadens the competitive frame. Roche, AstraZeneca, Teva, Novo Nordisk and Merck KGaA are prominent holdings 2, while UnitedHealth, CVS and Cigna provide substantial healthcare-services exposure 2. The result is a diversified set of pharmaceutical, metabolic-health, specialty-medicine, services and biotech exposures. Any LLY analysis should therefore distinguish broad pharmaceutical-sector tailwinds from company-specific advantages: this evidence supports the former, but offers no direct evidence for the latter.
Geographic and Thematic Positioning
Healthcare remains relatively out of favor compared with technology in capital flows 2, despite PCGH’s strong recent returns 2. The trust’s 59.2% allocation to the United States is 8.2 percentage points below its benchmark 2, while Denmark, Switzerland, Japan and India are overweight 2. PCGH also maintains a 25.4% biotech overweight 2 and an overweight position in small- and mid-cap biotech 2.
These exposures show that the healthcare opportunity set is being pursued through global diversification and higher-beta innovation, rather than through a simple concentration in US mega-cap pharmaceuticals. The emergent behavior is important: even where pharmaceutical exposure is rising, specialist managers are not merely buying the largest domestic companies. They are combining established pharmaceutical businesses with international positions, healthcare services and smaller biotechnology companies whose returns may be more sensitive to clinical, regulatory and financing conditions.
Performance, Gearing and Market Structure
PCGH’s performance record is strong on a net asset value basis, although the market-price experience is more mixed. Its five-year NAV return was 50.2%, versus 27.6% for its benchmark 2, and its one-year alpha was reported at 15.4% 2. During the three months ended June 30, 2026, PCGH’s NAV total return was 18.3%, compared with 17.2% for the NASDAQ Biotech Index 2.
The trust’s share-price results tell a different story. Its five-year share-price return of 71.3% trailed the MSCI ACWI’s 79.3% 2, while its one-year price return of 34.8% trailed the NASDAQ Biotech’s 61.7% 2. These figures are not contradictory. They measure different components of performance—NAV versus share price—and use different benchmarks. The distinction matters because an investment trust’s shareholder return can reflect not only the underlying portfolio, but also changes in the discount or premium at which the trust trades.
That market-structure effect is currently visible. PCGH traded at a 1.2% premium to NAV on July 9, 2026, compared with a 12-month range extending from a 5.0% discount to a 2.9% premium 2. The move from discount to premium occurred in late 2025 2. Such a premium is considered unusual for an investment trust and carries reversion risk 2. Strong healthcare performance, therefore, should not be treated as a straightforward valuation signal for the sector or for LLY. Some of the observed return may reflect multiple expansion or changes in the trust’s market rating rather than operating improvement alone.
PCGH’s 8.4% net gearing can amplify both upside and downside 2. One claim describes the position as a negative 8.4% cash/gearing figure 2; this is best understood as a difference in sign convention rather than a substantive contradiction. Leverage increases the sensitivity of shareholder outcomes to portfolio performance and market sentiment, making the trust’s returns more variable than an unlevered portfolio’s.
Governance changes may have helped address the structural discount. The trust’s 22.47% tender at the 2025 exit offer 2, together with shareholder-approved reforms including buyback authority and recurring five-year exit opportunities 2, may have reduced the persistent discount to NAV. They do not eliminate market-price risk, however. The premium can still revert, and gearing can still magnify the effect of a decline in the underlying portfolio.
Implications for Eli Lilly
For LLY, the principal signal is a tension between meaningful specialist demand for pharmaceutical innovation and an equity market still heavily influenced by technology and AI narratives. PCGH’s 42.3% pharmaceutical allocation, its increased pharmaceutical representation among its largest holdings and its emphasis on biotech indicate that healthcare specialists continue to identify opportunities in businesses with differentiated clinical or commercial prospects 2. At the same time, the comparison with technology in capital flows 2, alongside Contrafund’s heavy allocation to AI, cloud and semiconductor infrastructure 1, shows the strength of the competing growth narrative.
The evidence also points to a more discriminating healthcare market. PCGH’s sharp reduction in healthcare equipment and the replacement of several former top-ten holdings with pharmaceutical and services companies 2 favor the interpretation that product-cycle strength, growth visibility and valuation discipline are becoming more important. That is directionally constructive for a company such as LLY if its innovation pipeline and commercial execution remain strong. It is not, by itself, proof of a company-specific advantage.
The performance data reinforce the need to separate fundamentals from market structure. PCGH’s NAV outperformance and 34.8% one-year share-price gain 2 coexist with a premium that may revert 2 and leverage that increases variance 2. For LLY, the practical conclusion is that sector rotation and multiple expansion should not be confused with durable operating momentum. The same discipline applies to PCGH: a strong portfolio result does not remove the need to examine valuation, gearing and the mechanism by which shareholder returns are produced.
Conclusion
The evidence is current—mostly published July 9–10, 2026, with portfolio data through May or July 9—but largely single-source at the individual claim level. The highest-confidence conclusions are consequently thematic. Healthcare allocation is shifting toward pharmaceuticals and biotech; technology continues to dominate growth-oriented capital; and specialist healthcare performance depends on security selection as well as on valuation and market structure.
For investors assessing LLY, PCGH is best used as a measure of the surrounding investment climate rather than as evidence of direct ownership or intrinsic value. It shows that specialist managers are willing to increase exposure to pharmaceuticals and innovation, while also demonstrating that healthcare returns can be shaped by international diversification, biotech risk, gearing and the premium or discount applied to the investment vehicle. The relevant question is therefore not simply whether healthcare is attracting capital, but which businesses can convert that capital into durable clinical, commercial and financial outcomes.
